我型我秀

中美博弈再升级！美国突然撤销对中企出口芯片许可，中国反制动作迅速，再减持448亿美元外汇。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

据观察者网报道，综合多家外媒消息，近日，拜登政府进一步收紧了对中国企业华为的出口限制，宣布撤销美国芯片企业高通和英特尔公司向华为出售半导体的许可证。美国国会众议院外交事务委员会主席麦考尔表示，这是阻止中国开发先进人工智能的关键之举。此举将阻止美国英特尔和高通出售给华为任何芯片，还称这两家公司和中国“走得过近”。另据美国商务部证实，目前已“撤销了对华为的部分出口许可”。相关消息人士表示，美国针对华为的新举措，将影响华为手机和笔记本电脑芯片供应。

美国切断美企与华合作，实际上是在倒逼中国企业进一步扩大自研力度，加大中国企业的自主性，美国此举看似是阻碍中国发展，其实是“自断后路”。近年来，随着中国企业的高速发展，美国“一家独大”的垄断地位逐渐被打破。

二 | 对此毫无办法的拜登政府，便开始以损失自身企业的办法，打压中美正常的技术合作以及贸易往来。殊不知，这样的限制措施其实是“伤敌八百自损一千”。

面对咄咄逼人的美国政府，中国也并未选择逆来顺受。就在美国出台最新限制措施后不久，中国的反制来了。根据金融时报报道，近日，国家外汇管理局发布了最新统计数据，截至2024年4月，中国的外汇储备规模为32008亿美元，较3月减少448亿美元。

三 | 此外，在持续坚持减少美国外汇的同时，数据显示，中国已经连续18个月增持黄金。

四 | 可以发现，美西方越是对中国的高科技领域进行打压和遏制，中国对美元的需求就越缩减。拜登政府不想让中国获得领先，那美国自己也不想有好日子过。

从美国一次又一次加码对中国企业的制裁措施，我们可以发现两点。首先，美国部分极端政客野心巨大，持续鼓动拜登对华施加高压。这次直接撤销美企出口许可，就是其鼓动挑拨的结果。其次，美国对华的制裁并不成功，或者说根本没有达到美国想要的效果。要不然美国也不会像“打补丁”一样，不断更新对华打压措施，增加对中企的限制。

中国是一个不惧挑战和苦难的国家，最不怕外国的打压和限制。美西方那个的“小院高墙”再坚固，也挡不住中国坚持走自主创新的道路。事实已经并将继续证明，美国卡不了中国的“脖子”。美国如今对华关上合作的大门，实际上是将市场腾出来，拱手让给中国企业。

而就中国这次迅速地反制动作而言，我们或许早就料到了美国会走这步棋，已经提前有了应对策略。从这一点就可以看出，中国不会让美国或者别国肆意侵犯自身利益。我国商务部也已经发出警告：中方将采取一切措施，维护中方合法正当权益。新的“风暴”已经来临，中美竞争存在升温的趋势，这再一次证明，和美国讲道理是讲不通的，中方的反制必须“一拳到肉”。